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Abstract 
Cohort studies have been central to the establishment of the known causes of 
cancer. To dissect cancer etiology in more detail, for instance for personalized risk 
prediction and prevention, assessment of risks of subtypes of cancer, and 
assessment of small elevations in risk, there is a need for analyses of far larger 
cohort datasets than available in individual existing studies. To address these 
challenges the US National Cancer Institute Cohort Consortium was founded in 
2001. It brings together 58 cancer epidemiology cohorts from 20 countries to 
undertake large-scale pooling research. The cohorts in aggregate include over nine 
million study participants, with biospecimens available for about two million of these. 
Research in the Consortium is undertaken by >40 working groups focussed on 
specific cancer sites, exposures, or other research areas. More than 180 
publications have resulted from the Consortium, mainly on genetic and other cancer 
epidemiology, with high citation rates. This paper describes the foundation of the 
Consortium, its structure, governance and methods of working, the participating 
cohorts, publications and opportunities. 
The Consortium welcomes new members with cancer-oriented cohorts of 10,000 or 
more participants and an interest in collaborative research. 
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Introduction 
For over 60 years, since Doll & Hill (1) and Hammond & Horn (2) demonstrated the 
ill-effects of smoking, and Case et al (3) demonstrated the hazards of dyestuff 
manufacture to the bladder, cohort studies have been the principal method to 
provide definitive evidence of the carcinogenicity to humans of noxious agents, 
behaviors, and other exposures. Almost every cause of cancer that is known was 
established by this means (4). Increasingly, however, the need to dissect cancer 
etiology in more detail, and to pursue risk factors with smaller effects, has meant that 
even the largest cohorts are proving to be too small – for instance, to assess risks 
from uncommon exposures, or of uncommon types or subtypes of cancer, or to 
examine interactions or risks in population subgroups. The advent of molecular 
genetics, often examining very small elevations or decreases in risk, and of 
personalized risk prediction, examining risks subdivided across multiple susceptibility 
strata, have exacerbated the problem. 
Existing cohorts, however, have tended to be limited in size by financial and practical 
constraints. They have frequently been recruited from a restricted subset of the 
population, for instance teachers (5) or nurses (6, 7), and, with notable exceptions 
such as the Multiethnic Cohort Study (8), have often been limited in ethnic diversity. 
Similarly, cancer-focused cohorts, with some exceptions (e.g. (5-7, 9, 10)), have 
tended to recruit study participants who were at least 35 years of age at baseline, to 
increase the numbers of incident cancers early in follow-up. Furthermore, study 
investigators have focussed most of their energy on their cohort’s areas of research 
strength.  Consequently, questionnaire data and biospecimens from these cohorts 
have often remained unused (or if used, greatly underpowered) for analyses that 
require larger numbers. 
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One potential solution to this problem has been to assemble ever-larger new cohorts 
(11, 12), but there are practical and financial limitations to the size of these, and new 
cohorts take many years before they accrue sufficient follow-up and outcome events. 
They have also tended to be of limited diversity by age, sometimes by sex, and 
usually by ethnicity and country. Pooling data from existing cohorts internationally 
can relatively cheaply and quickly provide cohort data on a very large scale, with 
diversity of populations and exposures, capitalizing on the investments already made 
in such cohorts and their follow-up.  
Foundation of the Cohort Consortium, and its initial objectives 
To address these challenges, and to exploit new opportunities such as advances in 
methods for molecular genetics, the US National Cancer Institute (NCI), led by Drs. 
Robert Hoover and Robert Hiatt, convened a meeting in 2001 with the principal 
investigators of several cancer epidemiology cohorts. The meeting was embedded in 
a wider strategy that NCI developed in relation to genetic risk factors, cancer risks, 
and strategies for prevention. 
These investigators agreed on the value of pooling projects to enable analyses that 
no one cohort, nor even a few cohorts in alliance, could do alone, while still allowing 
the individual cohorts to meet their own scientific objectives. Another contributor to 
the ethos was the Pooling Project of Prospective Studies of Diet and Cancer (13), 
started in 1991, which includes many of the studies within the Consortium, and now 
forms a Working Group within it. The NCI therefore created the Cohort Consortium, 
initially fostering within it the Breast and Prostate Cancer Cohort Consortium (BPC3) 
(14), which examined risks of breast and prostate cancers, using a nested case-
control design within each of nine cohorts. BPC3 initially assessed risks in relation to 
germline variants in more than 60 candidate genes related to steroid hormone 
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metabolism and the IGF pathway (15-17) with greater precision than previously 
available and then, taking advantage of the rapidly declining costs of genomic 
assays, conducted a series of genome-wide association studies (GWAS) of these 
cancers (18, 19). The infrastructure and collaborative trust built up over time were 
central to the success of these GWAS. 
Structure and operations of the Consortium 
The Consortium has since grown greatly in size and scope. It now comprises over 
200 scientists from multiple institutions internationally, who have agreed to 
participate in collaborative research efforts and to pool data from their cohorts to 
address scientific questions that cannot otherwise be addressed through single 
institutions and cohorts. 
Governance and leadership 
The Consortium’s bylaws (https://epi.grants.cancer.gov/Consortia/bylaws.html)  
describe its current overall governance structure and the roles and responsibilities of 
the steering committee, Consortium members, and NCI staff, and are designed to 
facilitate dynamic, collaborative research, for instance by frequent rotations of the 
steering committee membership, and by each cohort having one vote on matters 
related to the Consortium.  
The Consortium activities are overseen by a steering committee elected by the 
members.  The steering committee is responsible for policy development, 
management, and setting the scientific direction.  It includes 6-9 principal 
investigators who reflect the institutional, geographic and gender diversity of the 
member cohorts, and three NCI ex-officio voting members representing the NCI 
Divisions of (i) Cancer Control and Population Sciences and (ii) Cancer 
Epidemiology and Genetics. The chair and chair-elect are elected by the steering 
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committee. Steering committee members are appointed for up to three three-year 
terms, and the chair for a one-year term. The overall day-to-day operations and 
technical support are managed by four NCI Executive staff.  
The steering committee holds monthly teleconferences to monitor the progress of 
ongoing Consortium studies and projects, address problems that arise in those 
projects, assess proposals for new scientific research projects and working groups, 
and organize the annual meeting.   
Membership 
There are currently 58 epidemiological cohorts in the Consortium, representing 
populations from 20 countries across four continents (North America, Europe, Asia, 
and Australia).  Membership of the Consortium is open, on application, to any cohort 
study with a minimum of 10,000 participants, in which cancer incidence is accurately 
assessed and some risk factor data are available. Membership also requires a 
general commitment to scientific collaboration through contribution of data for 
pooling research, but for each specific pooling project, individual cohorts decide 
freely whether or not they wish to participate. Membership is granted after a review 
of the application and a vote of the steering committee. 
Annual meetings 
The Consortium members meet annually in person to review progress, gain updates 
on ongoing and new projects, discuss new research ideas, share study results, and 
address methodological challenges. The content of the annual meetings is decided 
by the steering committee and the practical organisation is by the NCI Leadership 
Staff. The meetings last 2-3 days, and include: talks by some individual working 
groups, reporting on their progress; talks on scientific methodology or on areas, e.g. 
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metabolomics, that have potential for use in cohort epidemiology; and interactive 
sessions about the working of the Consortium. In addition the annual meetings  
provide a forum for individual Consortium working groups to meet to progress their 
pooling research. Such working group meetings may be open to all attending the 
Consortium meeting, or limited to cohorts participating in the working group, for 
instance because confidential new results are to be shown, including cohort-specific 
results from cohorts that have not yet published their own data separately. 
Working groups and new research projects 
The collaborative research in the Consortium is conducted by investigator-led 
working groups, of which there are currently more than 40. The steering committee 
assesses proposals monthly for new projects and hence for new working groups. 
Proposals from non-members are evaluated on the same basis as those from 
members of the Consortium. The proposals are made on a standard form that 
captures the rationale, design and proposed funding sources for the intended 
research, and practical details such as the minimum number of incident cancers that 
will be required for a cohort to join the particular pooling study. Each proposal is 
evaluated by the Consortium steering committee, based on the need for 
prospectively collected data/samples pooled from multiple cohorts, whether there is 
overlap or duplication of efforts by existing working groups, and the project’s 
potential to make a novel contribution to scientific research and public health.  Initial 
appraisal frequently leads to a request to the proposer for clarification or further 
information, with the intention to improve the clarity of the proposal to individual 
cohort members of the consortium and hence improve the chance that these cohorts 
will take part. The great majority of proposals are either then accepted by the 
steering committee to be disseminated to members as new working groups, or 
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directed toward joining an existing working group as a sub-project. Although 
approval by the steering committee is required for a new working group to be 
formed, decisions on subsequent research or spin off projects within an existing 
working group are the responsibility of the group itself. 
Once a working group is formed, participation of cohorts in the group is solicited by 
an email from the steering committee to members, and then direct communication by 
the lead investigator. The great majority of working groups go on to conduct and 
publish research successfully, but occasionally one does not, because the research 
proves to be infeasible (e.g. there are fewer cases than had been anticipated), or too 
few investigators choose to join, or the researchers have not been able to obtain 
funding.  
Communications 
A growing, large scale international consortium of this kindrequires effective and 
efficient bi-directional communication to maximize collaborations and productivity. A 
news letter, including information on new projects, is sent to Consortium members 
monthly. Webinars are used to host virtual meetings of working groups, as well as in 
conjunction with the in-person annual meetings to include members who cannot 
attend.  Working groups provide regular progress updates on their projects to the 
steering committee in conference calls, to discuss accomplishments, challenges, 
lessons learned and suggestions to improve the working of the consortium. They 
also share their study results through oral and poster presentations at the annual 
meeting.  
A secure portal, with access limited to consortium members, has been created to 
foster collaboration and information sharing. The portal serves as a repository and 
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archive for all consortium related activities including concept proposals, operational 
guidelines, historical documents and best practice documents, and is used by the 
scientific working groups for research activities. Individual working groups and 
projects are able to set up private work spaces within the portal with access limited 
to members of that working group. Several, but not all, working groups have used 
the portal in varying capacities for sharing updates, study policies and protocols, 
data, and manuscript versions, among their members.  
Current Consortium projects and working groups 
Overview 
Most Consortium working groups have focussed on specific cancer outcomes (e.g. 
pancreatic cancer, or ovarian cancer), while others have focussed on particular 
exposures (e.g. diabetes, or alcohol), or a combination of the two (e.g. circulating 
carotenoids and breast cancer risk, or vitamin D and risk of rare cancers). Others 
have related to particular ethnic groups, notably the African American BMI and 
mortality pooling project, which includes over 200,000 African Americans from seven 
cohorts. Several working groups (including five at present) have conducted GWAS. 
A small number have addressed rare cancers, for instance male breast cancer and 
renal cell cancers, and a few have investigated causes of cancer mortality or general 
mortality. 
Working groups are encouraged to remain open to new members joining provided 
that the new cohorts meet the minimum analysis-specific criteria: currently 29 of the 
working groups are open to new members. Reasons why working groups may at 
some point elect to close to new members are: that they were formed for a particular 
project and are now completing existing analyses before winding up; that their 
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funding (especially for laboratory assays) will not cover further cohorts joining; or that 
adding further cohorts, and the data transfer agreements and data harmonization 
entailed, would seriously delay analyses already well underway. 
Operations and organization 
The organization of individual projects and working groups varies. Most are led by 
the proposing investigator(s). Sometimes a steering committee is formed to manage 
activities and help with decision-making. The structure of working groups has varied 
widely. Some, for instance, have extensive written ground rules, publication 
guidelines, etc., while other are informal with no written rules. Some have continued 
for 10 years or more, accruing new analyses and purposes over time, while others 
have been formed for and conducted a specific investigation (e.g. a particular 
assay), published it, and disbanded. It is a strength of the Consortium that the 
collaborative arangements for working groups are flexible and in the hands of the 
members of each working group; additionally since most cohorts are members of 
many working groups, there is a great deal of expertise and experience from 
previous working groups to be drawn upon when creating new ones. 
The Consortium supports the development of the next generation of cancer 
epidemiology researchers by encouraging junior investigators to assume leadership 
and other active roles in managing Consortium studies, for instance as leaders of 
spin-off projects. Funding for projects varies, as described below.  
Details of the working groups and their accomplishments can be found on the 
Consortium’s website (https://epi.grants.cancer.gov/Consortia/members/#members).  
The Consortium steering committee and NCI provide overall support to the working 
groups by fostering communication, providing networking opportunities, and 
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providing limited administrative resources. To facilitate data sharing and data 
harmonization the NCI has funded the Cancer Epidemiology Descriptive Cohort 
Database (CEDCD) (https://cedcd.nci.nih.gov/), and two data repositories, the 
Cohort Metadata Repository (CMR) (https://cmr.nci.nih.gov/) and the Cancer 
Epidemiology Data Repository (CEDR) (https://epi.grants.cancer.gov/CEDR/), 
described in Table 1. The CEDCD allows investigators to search for the types of data 
and biospecimen that were collected by each cohort study, numbers of cohort 
participants and numbers of incident cancers, in order that investigators planning a 
consortium project can determine which cohorts have data on the specific variables 
of interest and potential numbers of subjects and cancers that might be available.  
The CMR is a tool that documents data harmonization processes, decisions and 
harmonized variables across cohorts that are participating in Consortium studies. It 
does not include individual-level data. Researchers interested in conducting pooled 
analyses in the consortium can view these metadata, including harmonized variables 
from specific projects and the specifications used to create them, to determine if they 
could use already-harmonized data sets for their analyses instead of undertaking a 
separate time-consuming harmonization effort. 
The CEDR is a controlled acess database developed to enable sharing of actual 
research data, while protecting the privacy of research participants. Researchers can 
deposit, access, and analyze a variety of individual-level de-identified data, ensuring 
that use aligns with specific data use agreements and informed consent for each 
study. 
Description of the participating cohorts  
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The cohorts taking part in the Consortium are shown in Table 2. They are 
contributing data from more than nine million study participants, and biospecimens, 
including germline DNA collected at baseline, from approximately 2 million 
participants.  
The majority (60%) of the cohorts are entirely or predominantly US-based, two are 
from Canada, 13 from Europe, six from south-east Asia, and one each from Mexico, 
Australia and  Iran. Most (66%) studies have less than 100,000 participants (40% 
less than 50,000 and 14% less than 20,000), 16 have 100,000-300,000 and four 
have over 500,000 participants. The vast majority of cohorts  restricted recruitment to 
adult ages, with 30 limited to people over age 35 years and 10 of those restricted to 
ages 50 and older. Three studies, all limited to women, restricted recruitment to 
younger participants (within the age range 25-55 years). Seventeen studies recruited 
only women and nine only men. Most studies were predominantly of whites.The vast 
majority of studies did not select on ethnic origin; exceptions were the Black 
Women’s Health Study and Southern Community Cohort Study (exclusively and 
predominantly African Americans, respectively), the Mexican American (Mano a 
Mano) Cohort, the Multiethnic Cohort Study (oversampled on several minority 
groups), and the Singapore Chinese Health Study. One study, the Radiation Effects 
Research Foundation Life Span Study, began in the 1950s, three in the 1970s, 18 in 
the 1980s, 21 in the 1990s, and the remainder since 2000.   
Primary objectives.  
Twenty-eight cohorts were established to investigate multiple causes of cancer, five 
of these for specific cancers only; the remainder aimed also to investigate other 
diseases or causes of death. Eight cohorts had as their primary aim to assess the 
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influence of diet on cancer and/or other diseases, and ten others focused on 
vitamins, minerals or other medications as potential preventative agents for cancer. 
Other cohorts were established to investigate specific risk factors such as radiation, 
exogenous sex hormones and genetics. 
Base populations.  
The cohorts were recruited using a variety of sampling strategies and target 
populations (Table 2). The largest group of cohorts were sampled from geographic 
regions or countries, several were from occupational groups, and 10 were leveraged 
from established cancer or cardiovascular randomized clinical or screening trials, by 
extending follow-up and collecting new exposures and outcomes.  To enrich for 
cancer risk, four cohorts sampled  high-risk families or siblings of cancer cases, two 
enrolled people with precursor conditions, and four sampled from people with known  
risk factors for cancer. Four cohorts were established from breast screening 
services.  
Outcome ascertainment. 
All cohorts in the Consortium follow participants for cancer incidence, with the 
majority linking to cancer registries and/or using regular follow-up questionnaires or 
telephone calls. Self-reported cancers are generally validated through medical or 
pathology record review.  To follow for overall mortality or cause of death, some 
cohorts link to existing data sources such as national, state or county death 
registries, or medical records; some also use active follow-up for these purposes. 
Several of the US cohorts including the VITamins and Lifestyle Study (Washington), 
the California Teachers Study, and the Multiethnic Cohort Study (Hawaii and 
California), purposely sampled regions covered by the NCI Surveillance, 
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Epidemiology, and End Results Program and other US population-based cancer 
registries, in order to obtain cancer incidence and survival data.  Non-cancer and 
non-death outcomes are ascertained via linkages to administrative databases (e.g. 
for hospital discharges and outpatients, and military records), as well as through 
direct contact with study participants: for instance the three Shanghai cohorts  
schedule ongoing in-person visits with cohort participants to obtain repeat 
measurements and health status over time. Half of the cohorts have gained further 
data directly from subjects by repeat questionnaires or in person visits, although the 
frequency varies greatly. Most cohorts collected blood samples from a least a subset 
of participants either at recruitment, or less often later. Several cohorts have 
collected tumor samples, for one or more cancer sites, for cancers incident in their 
cohort. 
Further details and contact information about the cohorts in the Consortium can be 
found on the website (https://epi.grants.cancer.gov/Consortia/members/#members) 
and in the Cancer Epidemiology Descriptive Cohort Database 
(https://cedcd.nci.nih.gov/). 
Practical considerations and challenges in conducting consortium-based 
projects 
Assembling a new pooling project is a complex and time-consuming endeavor. 
Consortium investigators have gained valuable experience in organizing such 
pooling successfully:-  
 Data acquisition and harmonization 
For most analyses conducted within the Consortium, gathering the necessary data 
from the participating cohorts, harmonizing and analyzing them, has been done at 
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one or two centers. While the NCI has on occasion conducted harmonization of the 
database and/or the statistical analyses for specific projects, these tasks have mostly 
been carried out by members of the working groups themselves, with the procedures 
then re-used for any further pooled projects within the working group. The 
Consortium has not in the past had a central data repository; members have 
generally preferred to provide data sets from their cohorts to the team conducting the 
analysis, rather than to a central entity. However, NCI has recently instituted a 
controlled-access repository, the CEDR, described above, where investigators can 
deposit individual-level de-identified data, to make their data more readily accessible 
by others and avoid having to respond to repeated data requests.  
Data harmonization is frequently highlighted by Consortium investigators as a major 
bottleneck, and one for which the workload tends to be underestimated. Questions 
and response categories for a particular exposure often differ between cohorts, and 
when harmonizing the data the exposure categories may have to be limited to fewer 
categories in common.  
The ease or difficulty of harmonization relates closely to the complexity, and degree 
of variety between studies, in the questions about, as well as the recording of, the 
risk factors. Relatively simple risk factors such as height and weight, tend to be 
relatively easy to harmonize, but even these can be problematic e.g. weights can be 
at different ages and because recording may have grouped weight into different, 
potentially incompatible, categories. More-complex variables such as diet and 
exercise have been more difficult, but nevertheless have been harmonized 
successfully – for instance, for exercise by converting the questionnaire responses in 
each study to Metabolic Equivalent of Tasks (METs). Socioeconomic variables can 
be difficult because they can be based on very different systems (e.g. salary, 
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education level, place of residence) in different countries. Serial exposures from 
baseline plus follow-up questionnaires can also be very difficult to harmonize 
because they reveal inconsistences between the serial responses. Age at 
menopause is exceptionally problematic to gain unambiguous data about, even 
within a single study and the more so for harmonization. 
New working groups have often harmonized data ab initio, in part because a different 
set of cohorts may be included than in previous working groups, and new analyses 
may require new algorithms and variables. To try to avoid each new Consortium 
working group having to re-harmonize the same cohorts’ data for each new project, 
the NCI developed the Cancer Metadata Repository described above. In 2013 the 
NCI supported a comprehensive harmonization of a large number of commonly used 
study variables for cohorts who chose to participate in the Diabetes and Cancer 
Initiative (n currently=28) and the code book from this harmonization is available in 
the CMR for other investigators. Greater use of such previously-developed study 
dictionaries and harmonization codes has the potential to speed up substantially the 
assembly of future pooled databases. The use of analytical platforms specifically 
adapted to harmonize and analyse epidemiological data from multiple sources, such 
as the Maelstrom research open-source software, (20), may further facilitate this 
process.   
Legal issues 
Over time, the legal constraints on data and material transfers have become more 
stringent. This has resulted in more-comprehensive and complex legal agreements 
(data and material transfer agreements) that stipulate the rules under which transfers 
of data or materials from individual cohorts are done. These agreements can be 
arduous and time-consuming to establish even for simple bilateral collaborations, but 
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they can lead to considerable delays for consortium projects involving dozens of 
institutions, each with different data sharing policies and often different national 
regulations, and with limitations imposed by different funders and employers. While 
the Consortium steering committee has established a pro forma template for data 
transfers, it remains to be determined if this will help facilitate future Consortium 
projects. Initiating the establishment of the necessary data and material sharing 
agreements as early as possible in a new consortium study is key to avoiding 
downstream delays. 
Governance and coordination of individual consortium projects 
There are no rules as to how individual pooling consortia assembled under the 
Consortium umbrella are governed. As noted above, some have been organized by 
an individual research group, others have a steering committee or multiple research 
groups leading different tasks or analyses. A common feature is a strong 
involvement of all investigators who wish to, in directing the research, such that in 
practice governance is by the participating cohorts, even though one or two groups 
may be central. 
The collaborative nature of Consortium studies is also reflected in how scientific 
contributions are recognized in the authorship of resulting publications – typically 
with one to three co-authors from each participating cohort, and sometimes with a 
writing group of a few consortium members who have undertaken initial data 
interpretation and drafting of a manuscript.  
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Financial aspects 
Obtaining sustained funding to maintain existing cohorts can itself be a major 
challenge, but without this, cohorts have limited capacity to contribute to a single, let 
alone multiple, consortial projects.  
Setting up a new Consortium project also involves costs, both for the coordinating 
group and to a lesser extent for each participating cohort. While “data only” studies 
have sometimes been realized on a relatively slim or no budget by leveraging 
existing resources, studies involving assays of biological samples are inevitably 
costly. Retrieving biospecimens from cohort biobanks, preparation of aliquots, 
shipping, and performing the relevant assays is expensive, and biomarker-based 
consortium studies have typically required substantial grants. 
When grants are obtained, these frequently include a small amount of support to 
each participating cohort, for instance, for preparation of the study database. NCI 
has developed and funded certain targetted initiatives within the Cohort Consortium 
to address NCI high programmatic and scientific research needs, but usually funding 
for projects has been obtained from investigator-initiated grants, from NCI or other 
sources. In the 171 published Consortium papers that stated funding sources, all but 
2 cited the US NCI as a source (but this can include support of individual cohorts, not 
just the overall pooling) and 30 cited other US NIH Institutes, especially the National 
Institute on Aging [22] and the National Institute of Environmental Health Sciences 
[14], while the American Cancer Society contributed to funding of 43. Three quarters 
of the papers cited funding solely from the US, and a tenth by 3 or more countries. 
Cohort consortium publications 
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The Consortium working groups have published 188 articles since the Consortium 
began in 2003 (https://epi.grants.cancer.gov/Consortia/publications.html). These 
articles are well cited, with an average of 9 citations each per year. Consortium 
papers have, on average, been cited over three times as often per year as the 
average NIH-funded paper in their field. They have particularly contributed on the 
role of common genetic variants in risk of various cancers(14-19, 21), a greater 
understanding of multifactorial contributors to common cancers (22, 23), 
understanding of the etiology of several less-common cancers or cancer subtypes 
(24-27), analyses with sample sizes sufficient to investigate risk factors for cancer in 
African Americans (28), and improved understanding of the shape of dose-response 
for risk factors for all-cause and cancer-specific mortality (23, 27-29).   
The vast majority of the papers [159 [85%]] were on cancer epidemiology (Table 3), 
mainly focussing on associations between genetic (51%) or lifestyle/anthropometric 
(27%) risk factors and cancer incidence [155] or less often for cancer survival [4] or 
cancer mortality [2]. These were mainly of nested case-control or cohort design, but 
in some instances also included non-cohort-based case-control studies to maximize 
numbers, for instance for genetic analyses (Table 4). The remainder of the papers 
covered epidemiology of other outcomes including mortality (most commonly all-
cause mortality) (4%), biomarkers (2%), mechanisms including DNA methylation and 
mosaicism (3%), and methodology for pooling projects (7%).  
The 94 papers on cancer genetics have included 29 on GWAS, nine of which were 
meta-analyses of GWAS. Twenty of the GWAS found novel risk loci and eleven 
confirmed previously reported risk loci. Forty-eight publications investigated 
candidate genes, individually or in pathways: 25 found significant associations with 
risk, while 23 had null findings. The remaining 17 studied pleiotropy [5], gene-
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environment interactions [8], or addition of genetics in risk models [4]. Studies of 
anthropometry, smoking and alcohol often found moderate associations with cancer 
risk, while studies of diet often gave less marked or null findings. A large number of 
studies examined the associations between pre-diagnostic biomarkers and cancer, 
most of which found no association with risk. 
Although the majority of cohort participants overall are white, there are sufficient non-
whites that 6 papers were published solely on Chinese and 2 solely on African 
Americans, as well as 12 with analyses stratified by ethnic group.    
Among the 159 cancer-related articles, the sites most frequently studied were breast 
(26%), prostate (22%) and pancreas (18%), but many papers also included less 
common sites (Table 3). In total, 67 of the papers were on cancers defined by the 
US National Cancer Institute as ‘rare’ (<15 cases per 100,000 per annum) and many 
of common cancers included subdivisions that require large numbers e.g. 17 papers 
on breast cancer subdivided by hormone receptor status, and papers on in-situ 
breast cancer and Type II endometrial cancer. The exposures analysed were in 
general relatively common (Table 3), but again large numbers enabled investigation 
of uncommon subsets within these (e.g. there were 2 papers on risks in 
metabolically healthy obese subject), and of subdivisions by more than one variable 
e.g. lung cancer risks in relation to vegetable intake and smoking, and liver cancer 
risks in relation to OC use and oophorectomy. For genetics, the need for large 
numbers was to enable the search for the relatively small elevations in relative risk 
that are typically present for individual SNPs , thus necessitating pooling even for 
analyses of common cancers. 
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Pooling successfully enabled analyses of large numbers of events, allowing greater 
power even for rare events than would have been possible in a single study. The 
average number of studies included in a manuscript was 10 and the average number 
of events was 7,026.  There was a tendency for the publications on rarer cancers to 
include a larger number of studies and a smaller average sample size. 
The average number of authors listed on the papers was 44, reflecting the team 
effort required for projects that combine studies; less than 15% of the papers had 15 
or fewer authors. The Cohort Consortium offered opportunities to many researchers, 
including many junior investigators. One hundred and eighteen unique investigators 
were first authors on the 188 papers. 
Conclusions 
The Cohort Consortium has come a long way from a group of investigators from nine 
like-minded cohort studies, all but two from the US, in 2001, to a collaboration now of 
58 cohorts from 20 countries. We have learned that cohort investigators are willing 
and eager to engage in large scale pooling projects, easily self-organize, and work 
productively with each other on studies that have yielded important findings with 
implications for understanding of etiology, clinical guidelines and public health 
measures. Over 180 publications have resulted, with productivity across a very wide 
range of aspects of cancer epidemiology research, as well as providing a forum for 
discussing and improving methods and best practice for cohort studies and pooling 
analyses.  
Critical to the success of the Consortium have been the provision of a central 
administrative and coordinating infrastructure by NCI, and the trust between cohort 
investigators,  expectation of reciprocity, and willingness to pool, that have built up 
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over the years. This is particularly critical because cohort studies are extraordinarily 
long-term, and individual investigators have often invested decades of work into 
them, so that the decision whether to join pooling efforts, which may invalidate future 
solo publications (e.g., on a rare tumour), is not a simple one. Trust has been greatly 
increased by the facilitative, non-prescriptive, bottom-up ethos of the Consortium, 
that it is driven by the research ideas of its members, with leadership by different 
research groups on different projects. 
The Consortium has provided an efficient means to bring together multiple diverse 
cohorts to address scientific questions the cohort investigators could not address on 
their own. The underlying cohorts in aggregate represent a huge investment, and 
have taken decades to collect follow-up data. The Consortium has, over a relatively 
short period produced important added value based on very large numbers. 
As a voluntary, investigator-led, collaborative framework, the future directions of the 
Consortium will depend on the wishes of its members. However, some general 
comments can be made. The opportunities that the Consortium has exploited, and 
will exploit in future, depend on funding constraints and incentives, the intrinsic 
strengths and limitations of the component cohorts, scientific opportunities and 
priorities, and the research interests of the members. Thus, for instance, there were 
many more gene-environment interactions, uncommon exposures and uncommon 
cancers that the Consortium could address in future, although the latter has the 
difficulty of a  lack of funding opportunities, (e.g. site-specific charities for common 
cancers such as breast tend to be much better resourced than those for rarer 
tumors). Furthermore, for very rare cancers or subtypes of cancers, even a 
consortium of this size may contain too few cases to generate precise risk estimates. 
The exposures that can be investigated with large numbers are limited to those for 
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which there are sufficient cohorts (and especially large ones) that collected data on 
these variables and to the level of detail that can be harmonised. Another limitation 
of the Consortial approach is the workload to involve large numbers of groups and 
investigators (although this is also a strength, because of the large number, and 
variety, of experienced investigators contributing to the quality of each publication). 
The strengths of consortial research, in particular compared with starting new 
cohorts, also include the long collective length of follow-up, and therefore the large 
numbers of incident cancers after recruitment already accrued, for immediate 
analysis, and the very low cost of combined analysis compared with the cost of 
initiating new cohorts. It would help to enable this if funding agencies made available 
funding initiatives aimed specifically at (a) maintenance and continuing follow-up of 
existing high quality cohorts and (b) large-scale pooled cohort analyses, especially 
for uncommon cancers, which collectively account for a large burden of mortality and 
morbidity but are individually difficult to fund. 
The Consortium needs to continue to expand, both to increase numbers for analyses 
of interactions, subgroup analyses and rare tumors and exposures, and to include 
more non-white populations, to enable larger analyses for these groups for which 
numbers within the Consortium are currently much fewer than for whites. The 
Consortium also needs to consider how to encourage and enable research on 
questions that currently are not addressed because no investigator has initiated 
investigation of the topic. Much of the 2017 annual meeting was spent discussing 
which research directions (e.g. rare tumors, rare exposures, gene-environment 
interactions) should be given priority in the next 5 years, and the steering committee 
is now formulating plans to address the priority areas. 
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There is great potential for the Consortium to contribute to future research, with 
opportunities provided by the wealth and growing volume of data and biospecimens 
available from the underlying cohorts, the changing landscape of cancer risk factors 
within and across populations (e.g., the growing worldwide obesity epidemic), and 
the extraordinary technological advances occuring in the assessment of genetic, 
metabolomic, and other molecular characteristics. The large sample sizes of the 
Consortium are advantageous both for discovering novel associations and for 
validating findings from individual studies. The move towards precision medicine and 
prevention (30, 31) will need reliable, stable risk estimates from cohort studies in 
ever-finer subdivisions of the population. As noted above, large cohort-based 
databases will also be needed to investigate rare cancers, rare exposures, and 
gene-environment interactions, to stratify risks by tumor subtypes, and to refine 
population-level and individual-level risk prediction. There are also great 
opportunities in survivorship research, and in biomarker research. The Consortium 
welcomes new members with cancer-oriented cohorts of 10,000 or more participants 
and an interest in collaborative research. 
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